Intuitive Surgical, the US-based pioneer of robotic-assisted surgery, saw its stock tumble in after-hours trading on Thursday after posting second-quarter results that fell short of Wall Street expectations. The company reported revenue of $2.01 billion for the three months ended 30 June 2026, against the consensus forecast of $2.08 billion, sending shares down more than 8% in extended trading.
The miss was driven by weaker-than-anticipated sales of its da Vinci surgical systems, particularly in Europe and parts of Asia, where hospitals have delayed capital equipment purchases amid ongoing budget pressures. Intuitive also lowered its full-year procedure growth forecast to between 12% and 14%, down from its previous range of 14% to 17%, citing a slower recovery in elective surgery volumes and supply chain disruptions affecting instrument delivery.
The news weighed on the broader medtech sector. In London, shares of Smith & Nephew, which competes in the orthopaedic and robotics space, slipped 1.4% in early trading on Friday, while FTSE 250-listed Convatec fell 0.8%. The FTSE 100 opened broadly flat, but the Stoxx Europe 600 Health Care index dipped 0.3% as investors reassessed growth expectations for the sector.
Analysts at Jefferies noted that while Intuitive's long-term prospects remain intact, the near-term headwinds are more pronounced than anticipated. 'The guidance cut suggests that hospital capital expenditure cycles are taking longer to recover, particularly in public healthcare systems like the NHS, which is a key customer for robotic surgery platforms,' they said in a note. For UK investors, the sell-off underscores the vulnerability of high-growth medtech stocks to changes in hospital budgets and procedure volumes.
The impact on UK pension holders is indirect but material, as many diversified pension funds hold US healthcare stocks through global equity allocations. The S&P 500 Health Care sector was down 0.6% in pre-market trading, and a sustained decline in Intuitive could drag on the performance of growth-focused funds. The broader market reaction also reflects concerns that similar headwinds may affect other robotic surgery developers, including London-listed CMR Surgical, which is privately held but watched closely by industry analysts.